SCHEMBL661620

SCHEMBL661620

COC(=O)c1ccc(CCC(=O)O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4A11 Q02928 2/20 0.64
CYP4F2 P78329 1/20 0.62
POLB P06746 1/20 0.60
LOXL2 Q9Y4K0 1/20 0.59
ALDH1A1 P00352 1/20 0.56
TP53 P04637 1/20 0.56
CYP1A2 P05177 1/20 0.56
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
HPGD P15428 1/20 0.56
ALOX15 P16050 1/20 0.56
ALOX12 P18054 1/20 0.56
CYP2C19 P33261 1/20 0.56
CKS1B P61024 1/20 0.56
SKP2 Q13309 1/20 0.56
HIF1A Q16665 1/20 0.56
HSD17B10 Q99714 1/20 0.56
FFAR1 O14842 5/20 0.55
CCR6 P51684 1/20 0.54
HKDC1 Q2TB90 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4199917 0.89 CYP4A11 (0.70) CYP4A11CYP4F2POLBLOXL2ALDH1A1
SCHEMBL2263222 0.88 CYP4A11 (0.71) CYP4A11CYP4F2POLBLOXL2ALDH1A1
SCHEMBL1643935 0.87 CYP4A11 (0.66) CYP4A11CYP4F2LOXL2ALDH1A1TP53
SCHEMBL1794544 0.86 CYP4A11 (0.69) CYP4A11CYP4F2POLBLOXL2ALDH1A1
SCHEMBL70185 0.86 CYP4A11 (0.75) CYP4A11CYP4F2LOXL2ALDH1A1TP53
SCHEMBL28900424 0.86 CYP4A11 (0.60) CYP4A11CYP4F2POLBLOXL2ALDH1A1
SCHEMBL2499088 0.85 CYP4A11 (0.64) CYP4A11CYP4F2LOXL2ALDH1A1TP53
SCHEMBL1629577 0.85 CYP4A11 (0.64) CYP4A11CYP4F2LOXL2ALDH1A1TP53
SCHEMBL11860304 0.85 FFAR1 (0.59) HSD17B10FFAR1KEAP1SRD5A2CA1
SCHEMBL23582799 0.84 LOXL2 (0.62) CYP4A11CYP4F2LOXL2ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2026-05-26 US disclosed
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2025-11-25 US disclosed
EP-3455204-B1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC (US) 2025-10-29 EP disclosed
EP-3778653-B1 NOVEL REACTIVE ALGINIC ACID DERIVATIVES MOCHIDA PHARM CO LTD (JP) 2025-07-09 EP disclosed
WO-2025011632-A1 HYDROXIMIC ACID COMPOUNDS CONTAINING TETRAHYDROBENZO[4,5]FURANO[2,3-C]PYRIDINE, PREPARATION METHOD THEREFOR, AND USES THEREOF 浙江大学 2025-01-16 WO disclosed
CN-114901653-B Novel amide derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof 株式会社LG化学 2024-11-22 CN disclosed
WO-2024067560-A1 SULFONAMIDE COMPOUND AND MEDICAL USE THEREOF 中国药科大学 2024-04-04 WO disclosed
CN-113582911-B Multi-target donepezil-hydroxamic acid compound, and preparation method and application thereof 山东大学 2024-03-12 CN disclosed
CN-117682973-A Sulfonamide compound and medical application thereof 中国药科大学 2024-03-12 CN disclosed
EP-4074701-B1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF LG CHEMICAL LTD (KR) 2023-12-13 EP disclosed
EP-1593667-A1 AMINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2005-11-09 EP disclosed
EP-1225173-B1 NAPHTHYRIDINE DERIVATIVES ASTELLAS PHARMA INC (JP) 2005-09-28 EP disclosed
US-6740662-B1 HAVING 2-OXO-1,2-DIHYDRO- FUNCTIONALITY; PHOSPHODIESTERASE INHIBITORS YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) 2004-05-25 US disclosed
EP-1225173-A1 NAPHTHYRIDINE DERIVATIVES YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) 2002-07-24 EP disclosed
EP-0858452-B1 THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS OTSUKA PHARMA CO LTD (JP) 2002-03-13 EP disclosed
CN-1070856-C Thiazole derivatives OTSUDA PHARMACEUTICAL CO LTD (JP) 2001-09-12 CN disclosed
US-6140330-A USEFUL AS PROTEIN KINASE INHIBITOR; FOR TREATMENT OF AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS, SYSTEMIC LUPUS ERYTHEMATOSUS, MULTIPLE SCLEROSIS, PSORIASIS, ETC., VARIOUS ALLERGIC DISEASES SUCH AS CROHN'S DISEASE, ASTHMA OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 2000-10-31 US disclosed
CN-1198160-A Thiazole derivative OTSUKA PHARMA CO LTD (JP) 1998-11-04 CN disclosed
EP-0858452-A1 THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1998-08-19 EP disclosed
WO-1998004536-A1 THIAZOLE DERIVATIVE AS PROTEIN KINASE C INHIBITORS OTSUKA PHARMACEUTICAL COMPANY, LIMITED (JP) 1998-02-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 CYP4A11 654/4885CYP4F2 1872/4885POLB 2099/4885
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, DLAT CYP4A11 1766/4885CYP4F2 1056/4885POLB 3273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.